0.686
-0.02 (-2.62%)
| Penutupan Terdahulu | 0.705 |
| Jumlah Dagangan | 364,043 |
| Harga / Buku (P/B) | 16.10 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -5.27 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.13% |
| Nisbah Semasa (MRQ) | 4.31 |
| Aliran Tunai Operasi (OCF TTM) | -69.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -43.72 M |
| Pulangan Atas Aset (ROA TTM) | -56.50% |
| Pulangan Atas Ekuiti (ROE TTM) | -101.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Jasper Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -1.5 |
| Purata | -0.33 |
|
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.27% |
| % Dimiliki oleh Institusi | 87.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2025 | 928,964 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |